Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHurley, James C.en
dc.description.abstractNumerous agents have been developed with specific binding and inhibitory activity against endotoxin which have all shown promise in preclinical evaluations through the protection of animals against endotoxin challenge. The results of the clinical trials of agents published to date have not met the expectations generated by the results of the pre-clinical studies. A concept not reflected in animal models is that Gram-negative sepsis is a heterogeneous entity: not all patients are either bacteraemic or endotoxaemic. Sub-groups of patients that could be recognised prospectively using newer methods may not respond equally to anti-endotoxin agents. The future success of these therapeutic modalities will probably depend on our ability to identify and target the therapies to those patients who will benefit most, possibly through the application of an assay for endotoxaemia.en
dc.description.provenanceApproved for entry into archive by Kimberley Asprey ( on 2012-09-04T02:02:17Z (GMT) No. of bitstreams: 0en
dc.description.provenanceSubmitted by Kimberley Asprey ( on 2012-09-04T01:57:39ZNo. of bitstreams: 0en
dc.description.provenanceMade available in DSpace on 2012-09-04T02:02:17Z (GMT). No. of bitstreams: 0 Previous issue date: 1995en
dc.publisherInforma Healthcareen
dc.titleEndotoxaemia and novel therapies for the treatment of sepsis: pulmonary-allergy, dermatological, gastrointestinal & arthritis.en
dc.typeJournal Articleen
dc.bibliographicCitation.titleExpert Opinion on Investigational Drugsen
Appears in Collections:Research Output

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.